| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
|
| ln Vitro |
Galactose plays a major role in the survival and pathogenicity of bacteria. In E. Galactose is mostly used by the Leloir pathway in E. Coli. Each of the three d-galactose terminal groups has a distinct function; α-d-galactose serves as a carbon source, while β-d-galactose stimulates the synthesis of UDP-galactose for the biosynthetic glycosylation process [1].
|
|---|---|
| ln Vivo |
In animal modeling, D-galactose can be utilized to create models of cataract tracking and mouse subacute dormancy. Chronic exposure to D-galactose increases oxidative damage, enhances caspase-mediated cell display, and inhibits neurogenesis and neural migration in mice, all of which lead to neurodegeneration. Moreover, D-galactose-induced sensitization is a helpful model for researching medication processes and neurodegenerative and neuroprotective treatments [2]. The ultimate suggested D-galactose route results in oxidative damage and cognitive impairment. Cognitive deficits were noted in the open field test at 4 and 6 weeks following the d-gal tower, whereas deficits in spatial memory were noted in the maze test at 6 weeks following the d-gal tower [3].
|
| References |
|
| Additional Infomation |
Aldehydo-D-galactose is a D-galactose and an aldehydo-galactose. It is an enantiomer of an aldehydo-L-galactose.
(2R,3S,4S,5R)-2,3,4,5,6-pentahydroxyhexanal has been reported in Camellia sinensis, Ascochyta medicaginicola, and other organisms with data available. Galactose is a metabolite found in or produced by Saccharomyces cerevisiae. An aldohexose that occurs naturally in the D-form in lactose, cerebrosides, gangliosides, and mucoproteins. Deficiency of galactosyl-1-phosphate uridyltransferase (GALACTOSE-1-PHOSPHATE URIDYL-TRANSFERASE DEFICIENCY DISEASE) causes an error in galactose metabolism called GALACTOSEMIA, resulting in elevations of galactose in the blood. See also: D-Galactose (annotation moved to). |
| Molecular Formula |
C6H12O6
|
|---|---|
| Molecular Weight |
180.1559
|
| Exact Mass |
180.063
|
| CAS # |
59-23-4
|
| Related CAS # |
D-Galactose-13C;70849-30-8;D-Galactose-13C6;74134-89-7;D-Mannose;3458-28-4;D-Galactose-13C-2;478518-56-8;D-Galactose-d2-1;1176791-08-4;D-Galactose-13C,d;370565-96-1;D-Galactose-13C-3;478518-58-0;D-Galactose-13C-4;478518-60-4;D-Galactose-13C-5;478518-62-6;D-Galactose-d;64267-73-8;D-Galactose-d-1;64429-86-3;D-Galactose-d-2;478518-70-6;D-Galactose-d-3;478518-71-7;D-Galactose-d2;35669-34-2
|
| PubChem CID |
3037556
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
527.1±50.0 °C at 760 mmHg
|
| Melting Point |
168-170 °C(lit.)
|
| Flash Point |
286.7±26.6 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.573
|
| LogP |
-3.17
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
12
|
| Complexity |
138
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C([C@H]([C@@H]([C@@H]([C@H](C=O)O)O)O)O)O
|
| InChi Key |
GZCGUPFRVQAUEE-KCDKBNATSA-N
|
| InChi Code |
InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h1,3-6,8-12H,2H2/t3-,4+,5+,6-/m0/s1
|
| Chemical Name |
(2R,3S,4S,5R)-2,3,4,5,6-pentahydroxyhexanal
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~62.5 mg/mL (~346.91 mM)
DMSO : ~50 mg/mL (~277.53 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (555.06 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5506 mL | 27.7531 mL | 55.5062 mL | |
| 5 mM | 1.1101 mL | 5.5506 mL | 11.1012 mL | |
| 10 mM | 0.5551 mL | 2.7753 mL | 5.5506 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
